trial summary · NCT07856797
A Study to Confirm Safety and Effectiveness of RADIESSE® Injectable Implant for the Correction of Moderate to Severe Nasolabial Folds
A Prospective, Open-Label, Multicenter, Post-Market Clinical Follow-Up Study to Confirm the Long-term Safety and Effectiveness of RADIESSE® Injectable Implant for the Correction of Moderate to Severe Nasolabial Folds
Trial record from the TrialBase DB dataset, status RECRUITING, condition Nasolabial Folds, sponsored by Merz North America, Inc.. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
The purpose of this study is to confirm the long-term safety, effectiveness, and degradation profile of RADIESSE® Injectable Implant for the correction of moderate to severe nasolabial folds (NLFs) in Chinese adults. Eligible participants will receive treatment with RADIESSE® Injectable Implant in both NLFs and may receive an optional touch-up treatment at Month 1 at investigator's discretion. Participants will be followed for up to 24 months after last treatment.
Source record: https://clinicaltrials.gov/study/NCT07856797
Facts
| registry id | NCT07856797 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | not reported |
| study type | INTERVENTIONAL |
| lead condition | Nasolabial Folds |
| sponsor | Merz North America, Inc. |
| sponsor class | INDUSTRY |
| enrollment | 163 |
| start date | 2026-10-27 |
| primary completion | 2027-08 |
| completion | 2029-02 |
| results posted | not reported |
Conditions
- Nasolabial Folds
Interventions
- Subdermal Implant
Countries
- China
Intervention types: DEVICE
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.